Please login to the form below

Not currently logged in
Email:
Password:

Eli Lilly & Co ethics upgrade

US firm agrees to employ ethics 'watchdogs' as part of lawsuit settlements

Eli Lilly & Co has announced it will create four new positions in senior management to promote ethical and compliant behaviour as part of the settlement of two lawsuits after the company was found guilty in 2009 of illegally marketing and promoting several of its drugs.

Under the settlement agreement, Lilly has agreed to create openings for a vice president of global compliance strategy, vice president of global ethics, a senior director of enterprise risk management and a project manager to implement and monitor new policies.

According to reports in US state newspaper the Indy Star, Lilly spokesman Mark Taylor said the new roles are in the process of being filled and all four people would report to Anne Nobles, chief ethics and compliance officer at the company. 

In 2009, the firm was fined $1.4bn – the largest criminal fine ever imposed on a US company – over the illegal marketing of Zyprexa. The drug, which is approved for use for the treatment of bipolar disorder and schizophrenia, was unlawfully promoted for the treatment of agitation, aggression, hostility, dementia, depression and generalised sleep disorder.

In addition, Lilly was also accused of improperly marketing osteoporosis drug, Evista and antidepressant, Prozac.

In response to the court ruling, a number of shareholders sued Lilly on the grounds that it breached fiduciary duty in connection with illegal marketing, exposing the company to significant risk of damage. The lawsuits, known as derivative claims, seek to force Lilly to take corrective steps.

Lilly has agreed to pay $35,000 to the named shareholders and pay $8.75m in legal fees, including $450,000 to plaintiffs.

The settlement, which has yet to be approved by a federal judge, covers two of seven outstanding 'derivative shareholder' cases spread across the courts.


 

9th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics